NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -0.95% | -2.86% | +2.77% |
May. 31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+2.77% | 13.63B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
+0.09% | 21.96B | |
-8.40% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+34.58% | 12.27B | |
+77.64% | 8.87B | |
+7.26% | 7.75B |